Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Drug Industry Perks Mostly Dropped From COVID-19 Bill, But A Big One Remains

Mar 27 2020

• By Sarah Karlin-Smith

Washington DC Capitol dome detail with waving american flag

Related Content

Buying The Coronavirus Vaccine: What Would A ‘Fair And Reasonable’ Price Be?

Mar 06 2020

Drug Pricing Reform In 2020 Gets Harder Due To Third Coronavirus Bill

Mar 25 2020

Part D Plans Would Need To Cover COVID-19 Drugs Without Cost Sharing Under House Bill

Mar 25 2020

Medicare Part B, Breakthrough Drugs Get Reimbursement Boost In Senate COVID-19 Bill

Mar 22 2020

Antibiotics May Finally Get Better Medicare Payments Under US Senate COVID-19 Aid Package

Mar 22 2020

Coronavirus Product Communications Would Get Safe Harbor Under Senate Bill

Mar 22 2020

Additional Topics

United States Coronavirus COVID-19 Pricing Debate Legislation FDA Lobbying Reimbursement BioPharmaceutical

More from Pricing Debate

More from Market Access

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window